Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Stitch Fix shares fell 18.2% pre-market to $2.31 after Q4 revenue of $324.42 million narrowly missed the $325.5 million consensus estimate and fiscal 2027 revenue guidance of $1.31 billion-$1.36 billion trailed the $1.41 billion Street forecast. Its adjusted loss of $0.02 per share beat the expected $0.06 loss, but weak sales guidance dominated investor reaction. MGM Resorts declined 8.3% after People Inc. withdrew its proposal to acquire MGM's public shares, while Viking Therapeutics also fell 8.3% following proposed public offerings.

Analysis

SFIX’s guidance reset matters less for broad apparel demand than for the viability of fixed-cost, human-assisted personalization at subscale. The revenue outlook implies continued difficulty spreading styling, fulfillment and customer-acquisition costs, leaving a low-margin model vulnerable even if topline stabilizes. Near term, the gap-down can invite technical short-covering given the low absolute share price; over 6-18 months, however, sustained evidence of shrinking active clients or rising fulfillment cost per order would re-open dilution/strategic-alternative risk. Off-price and scaled digital apparel platforms—including TJX, ROST, AMZN and TGT—are relative beneficiaries if consumers are migrating toward value and immediacy rather than curated subscription discovery.

MGM’s broken-deal move removes an event-driven valuation floor and shifts attention back to Las Vegas margin normalization, regional-gaming competition and leverage. The key second-order issue is that a withdrawn bidder may signal either price disagreement or financing/underwriting constraints; absent a new credible bidder within 30-60 days, merger-arb holders can become forced sellers. This is more consequential for MGM than for asset-light peers such as CZR, whose earnings sensitivity to Strip room rates and digital gaming should determine relative performance after the technical unwind.

VKTX’s financing is strategically rational only if capital raised extends the runway through value-inflecting obesity data and manufacturing commitments; the market will discount it as a dilution overhang until use of proceeds and post-offering float are clear. The relevant comparison is not current cash alone but whether VKTX can preserve negotiating leverage versus LLY/NVO and potential partners. FSLY’s retracement after target-price-driven strength is not a fundamental negative: it is a useful test of whether incremental institutional demand exists beyond sell-side momentum, but there is insufficient evidence here for a directional position.

Key Decisions for Investors

• Maintain/establish SFIX short only on a failed rebound below $2.60-$2.75 over the next 1-3 weeks; target $1.70-$1.90 over 3-6 months if active-client and gross-margin trends do not improve. Cover on evidence of sequential client growth plus fulfillment-cost leverage, or on a credible strategic transaction.
• Trade MGM as an event unwind rather than a fundamental short: avoid chasing the opening dislocation; sell rallies toward the pre-withdrawal trading range if no new bidder emerges within 30 trading days. A cleaner relative expression is short MGM / long CZR in equal beta for 1-3 months, with stop if MGM announces a financed superior proposal or Strip booking commentary materially improves.
• Do not buy VKTX into the offering until pricing, size and use of proceeds are disclosed. Watch for a post-pricing stabilization and a cash runway extending beyond the next major clinical/manufacturing catalysts; then consider a 6-12 month call-spread rather than outright equity, with the thesis invalidated by unexpectedly deep discounting or a runway still requiring another raise before pivotal data.
• Use FSLY weakness as a watch-list entry, not an immediate trade: initiate only if it holds above the prior-day breakout support on elevated volume and management corroborates growth/margin inflection at the next update. Failure to hold that level would indicate the move was primarily analyst-flow driven.